Hatz H J, Helmke K
IV. Med. Abteilung/Rheumatologie und Immunologie, Städt. KH München-Bogenhausen.
Z Rheumatol. 1992 Sep-Oct;51(5):213-21.
Due to good therapeutic results and few side-effects so-called "low-dose glucocorticoid therapy" (ldgc) with daily glucosteroid dosage below 10 mg prednisolone-equivalent has recently been recommended in managing polymyalgia rheumatica and giant cell arteritis. This fact is of important interest, since mean therapy time is often over a period of five years. An open-prospective study with 75 patients in a rheumatological unit was done in which different clinical histories were examined and glucosteroid side effects of 47 patients who had received therapy over six months were analyzed. Main side-effect shown was osteoporosis (n = 7), other known steroid-side effects were quite seldom (less than 5%). Dosage regimens and therapy monitoring criteria are proposed.
由于治疗效果良好且副作用较少,近来有人推荐采用所谓的“低剂量糖皮质激素疗法”(ldgc)来治疗风湿性多肌痛和巨细胞动脉炎,该疗法每日糖皮质激素剂量低于10毫克泼尼松等效剂量。鉴于平均治疗时间通常超过五年,这一事实具有重要意义。我们在一个风湿病科对75名患者进行了一项开放性前瞻性研究,研究中检查了不同的临床病史,并分析了47名接受治疗超过六个月的患者的糖皮质激素副作用。主要的副作用表现为骨质疏松(n = 7),其他已知的类固醇副作用则相当少见(少于5%)。文中还提出了给药方案和治疗监测标准。